This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kobayashi, H. Articles by Carrasquillo, J. A. Search for Related Content PubMed PubMed Citation Articles by Kobayashi, H. Articles by Carrasquillo, J. A.

The Pharmacokinetic Characteristics of Glycolated Humanized Anti-Tac Fabs Are Determined by Their Isoelectric Points

Department of Nuclear Medicine, Warren G. Magnuson Clinical Center [H. K., N. L., I-s. K., M-K. K., J-E. P., D. D., D. S. P., C. H. P., J. A. C.], and Metabolism Branch, Division of Clinical Sciences [T. A. W.], National Cancer Institute, NIH, Bethesda, Maryland 20892-1180

To evaluate a method for preventing the nephrotoxicity caused by the high renal accumulation of radiolabeled or toxin-conjugated small immunoproteins used for cancer therapy, we conjugated humanized anti-Tac Fab fragments with various numbers of glycolate molecules [glycolated Fab fragments (glyco-Fabs)] and separated the conjugates by means of ion-exchange columns into three fractions, depending on their isoelectric points (pIs). We evaluated the biodistribution, pharmacokinetics, and catabolism in normal nude mice of nonglycolated Fab (pI 9.3) and three different preparations of glyco-Fab, including strongly anionic glyco-Fab (sa-glyco-Fab: pI 4.5), mildly anionic glyco-Fab (pI = 4.5–7), and mildly cationic glyco-Fab (pI = 7–9.3). In addition, the biodistributions of ¹²⁵I-labeled sa-glyco-Fab and ¹³¹I-labeled nonglycolated Fab were evaluated in normal nude mice coinjected with 50 mg of L-lysine and/or 1 µg of furosemide and in a control group without coinjection. We then evaluated the serial biodistribution of ¹²⁵I-labeled sa-glyco-Fab (4 µCi/1 µg) and ¹³¹I-labeled nonglycolated Fab (5 µCi/1 µg) in Tac antigen-positive (ATAC4) and -negative (A431) tumor-bearing nude mice with s.c. tumor xenografts derived from Tac antigen-positive ATAC4 cells and receptor-negative A431 cells. These animals were coinjected with 30 mg of lysine i.v. and 30 mg of lysine i.p. 15 min after the radiolabeled Fab injection. To evaluate the biodistribution data and study scintigraphic imaging, we performed serial scintigraphy on normal and tumor-bearing mice with all four ¹³¹I-labeled preparations. ¹²⁵I-labeled mildly cationic glyco-Fab and ¹³¹I-labeled nonglycolated Fab had similar distributions, except in the kidney. However, both ¹²⁵I-labeled anionic glyco-Fab preparations showed significantly different distributions from both cationic Fabs in the blood, liver, lung, and spleen. Renal accumulation of all four radiolabeled Fab preparations increased significantly as the pI increased (P < 0.01). In addition, the intact fraction of Fab excreted into urine increased as pI decreased. Therefore, the glomerular filtration depended on whether the charge on the Fab was positive or negative. The proportion of Fab reabsorbed by the proximal tubules increased as pI increased. ¹²⁵I-labeled sa-glyco-Fab and ¹²⁵I-labeled mildly anionic glyco-Fab showed a similar distribution in the blood and all organs except the kidney. Lysine led to an additional blocking effect on proximal tubular uptake of both sa-glyco-Fab and nonglycolated Fab. Addition of furosemide yielded only a small effect when used with lysine. With lysine, the sa-glyco-Fab:nonglycolated Fab estimated integral radioactivity ratios were 4.7 and 0.7 in the ATAC4 tumor and in the kidney, respectively. The use of anionic fragments, which may be used in conjunction with lysine, represents a promising approach that may help decrease the renal toxicity of other small fragments, the molecular weights of which range from M_r 40,000 to 70,000, and, thereby, allow higher doses of radiation to the tumor.

This article has been cited by other articles:

				H. Kobayashi, K. Reijnders, S. English, A. T. Yordanov, D. E. Milenic, A. L. Sowers, D. Citrin, M. C. Krishna, T. A. Waldmann, J. B. Mitchell, et al. Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation Clin. Cancer Res., November 15, 2004; 10(22): 7712 - 7720. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, Z. Yao, K. S. Lam, A. Song, P. A. Burke, G. R. Mirick, K. R. Lamborn, R. T. O'Donnell, and G. L. DeNardo Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice Clin. Cancer Res., September 1, 2003; 9(10): 3854s - 3864s. [Abstract] [Full Text]

				M. Onda, S. Nagata, Y. Tsutsumi, J. J. Vincent, Q.-c. Wang, R. J. Kreitman, B. Lee, and I. Pastan Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity Cancer Res., July 1, 2001; 61(13): 5070 - 5077. [Abstract] [Full Text] [PDF]

				H. J.J.M. Rennen, O. C. Boerman, W. J.G. Oyen, J. W.M. van der Meer, and F. H.M. Corstens Specific and Rapid Scintigraphic Detection of Infection with 99mTc-Labeled Interleukin-8 J. Nucl. Med., January 1, 2001; 42(1): 117 - 123. [Abstract] [Full Text] [PDF]